Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$2.73 USD
+0.01 (0.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.72 -0.01 (-0.37%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABUS 2.73 +0.01(0.37%)
Will ABUS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABUS
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
ABUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
Other News for ABUS
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Tourlite Capital Q1 2024 Investor Letter
Moderna Investors Should Beware Patent-Dispute Fallout
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update